1314 related articles for article (PubMed ID: 24104372)
1. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Oettle H; Neuhaus P; Hochhaus A; Hartmann JT; Gellert K; Ridwelski K; Niedergethmann M; Zülke C; Fahlke J; Arning MB; Sinn M; Hinke A; Riess H
JAMA; 2013 Oct; 310(14):1473-81. PubMed ID: 24104372
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
[TBL] [Abstract][Full Text] [Related]
3. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Jones RP; Psarelli EE; Jackson R; Ghaneh P; Halloran CM; Palmer DH; Campbell F; Valle JW; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ting Y; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Lerch MM; Mayerle J; Tjaden C; Strobel O; Hackert T; Büchler MW; Neoptolemos JP;
JAMA Surg; 2019 Nov; 154(11):1038-1048. PubMed ID: 31483448
[TBL] [Abstract][Full Text] [Related]
5. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
[TBL] [Abstract][Full Text] [Related]
7. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Conroy T; Castan F; Lopez A; Turpin A; Ben Abdelghani M; Wei AC; Mitry E; Biagi JJ; Evesque L; Artru P; Lecomte T; Assenat E; Bauguion L; Ychou M; Bouché O; Monard L; Lambert A; Hammel P;
JAMA Oncol; 2022 Nov; 8(11):1571-1578. PubMed ID: 36048453
[TBL] [Abstract][Full Text] [Related]
8. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
[TBL] [Abstract][Full Text] [Related]
10. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
Van Laethem JL; Hammel P; Mornex F; Azria D; Van Tienhoven G; Vergauwe P; Peeters M; Polus M; Praet M; Mauer M; Collette L; Budach V; Lutz M; Van Cutsem E; Haustermans K
J Clin Oncol; 2010 Oct; 28(29):4450-6. PubMed ID: 20837948
[TBL] [Abstract][Full Text] [Related]
12. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
[TBL] [Abstract][Full Text] [Related]
13. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.
Ueno H; Kosuge T; Matsuyama Y; Yamamoto J; Nakao A; Egawa S; Doi R; Monden M; Hatori T; Tanaka M; Shimada M; Kanemitsu K
Br J Cancer; 2009 Sep; 101(6):908-15. PubMed ID: 19690548
[TBL] [Abstract][Full Text] [Related]
17. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine in node-positive pancreatic cancer.
Kurosaki I; Hatakeyama K
Hepatogastroenterology; 2004; 51(57):634-7. PubMed ID: 15143880
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Deplanque G; Demarchi M; Hebbar M; Flynn P; Melichar B; Atkins J; Nowara E; Moyé L; Piquemal D; Ritter D; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Hammel P
Ann Oncol; 2015 Jun; 26(6):1194-1200. PubMed ID: 25858497
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
Kurosaki I; Hatakeyama K
Chemotherapy; 2005 Oct; 51(6):305-10. PubMed ID: 16224180
[TBL] [Abstract][Full Text] [Related]
20. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
